Embed Size (px)
Citation preview
1
How to Empower Patients and Advocacy Organizations through Collaboration
Rare Cancers
December 9, 2016
2
Panelists
Martine EliasDirector of Access, Advocacy & Community Relations Myeloma Canada
David JosephyPresidentGIST Sarcoma Life Raft Group Canada
Durhane Wong-RiegerPresident & CEO Canadian Organization for Rare Disorders (CORD)
3
GIST Sarcoma Life Raft Group Canada
Gastrointestinal Stromal Tumour:
• a rare sarcoma
• Several effective oral drugs (targeted TKIs)
• LRGC is a registered charity
• >125 members across Canada
• Our Vision: To support activities resulting
in a cure for GIST, bringing every Canadian
affected by this rare cancer onto our Life
Raft until we achieve that goal
• Annual Day of Learning and occasional
local patient gatherings
4
OUR MISSION Myeloma Canada is the only national non- profit organization uniquely devoted to the Canadian myeloma community. Founded in 2005 by two myeloma patients, Myeloma
Canada is a patient-driven, patient-focused grassroots organization, whose goals are to:
Provide educational resources and support to patients, families and caregivers
Increase awareness of the disease and its effects on the lives of patients and families
Facilitate access to new therapies, treatment options and heath care resources
Foster, support and fund Canadian Research efforts to improve patient outcomes and ultimately help find a cure for myeloma
5
• Canadian Organization for Rare Disorders
(CORD) — Network of 102 Patient Groups
• Mission: Improve lives of all those affected
by rare diseases
• Mandate: Advance rare disease policy;
improve screening, diagnose and access to
clinical trials and treatment; develop
patient group capacity; support research;
collaborate
• Durhane Wong-Rieger, PhD,
President and CEO
Ottawa, ON Rare Disease Day 2016 Parliament Hill
6
What we will discuss• Introduction to rare cancers and key issues• Rare cancers, small but mighty patient groups!
– Life Raft Group (gastrointestinal stromal tumors)
– Myeloma Canada• Collaboration across patient organizations
and lessons learned from abroad– Europe
– Australia• Qs and As
7
Definitions - What’s a Rare Cancer?
8
One of the Challenges: Impact vs. Attention and Research – Australia Data
2015 Cancer Audit
9
Screening – Diagnosis – Prevention
10
Access to Specialists and Referrals
11
Regulatory Challenges and Issues
12
Health Technology Assessment Programs – Evaluation Opportunities and Challenges
13
Treatment Pathways
• Companion diagnostics• Clinical trials - access to the latest therapies• Off-label use and access• Reimbursement• Sequencing and treatment
guidelines
14
National and Provincial Rare Disease and Orphan Drug Strategies - What Would They
Mean for Rare Cancers?
15
Attention and Awareness
16
For Organizations - What Are the Challenges - Administratively, etc…
17
Is There an Opportunity or a Need for the Rare Cancers Community to Come Together? What
can we learn from other jurisdictions?
18
Final Thoughts
• For the individual caregivers and patients on the line - what can they do?
• For groups, how can they work together? CORD, CCSN, etc.
• Next steps for the cancer survivor community more broadly
19
21
Canadian Cancer Survivor Network Contact Info
Canadian Cancer Survivor Network1750 Courtwood Crescent, Suite 210Ottawa, ON K2C 2B5Telephone / Téléphone : 613-898-1871
E-mail: [email protected] or [email protected]
Web site: www.survivornet.ca
Blog: http://jackiemanthornescancerblog.blogspot.com/Twitter: @survivornetca
Facebook: www.facebook.com/CanadianSurvivorNet
Pinterest: http://pinterest.com/survivornetwork/
